GSEP
PYXS icon

Golden State Equity Partners’s Pyxis Oncology PYXS Stock Holding History

Golden State Equity Partners’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$14 – 1400
2026
Q1 		$14 Buy
+10
New +$15 ﹤0.01% 2012

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Golden State Equity Partners's PYXS Position: Q2 2026 in Review

Golden State Equity Partners sold out of Pyxis Oncology (PYXS) in Q2 2026, closing a stake of 10 shares — an estimated $14 sold.

Golden State Equity Partners first reported a position in PYXS in Q1 2026 and held it in 1 quarter. The position peaked at $14 in Q1 2026. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Golden State Equity Partners reported no remaining Pyxis Oncology position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 10 Pyxis Oncology shares in Q2 2026, an estimated $14.
  • Golden State Equity Partners first reported a position in Pyxis Oncology in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Pyxis Oncology position peaked at $14 in Q1 2026.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.